Promising prostate cancer trial pulled before it even started
NCT ID NCT06528210
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 28 times
Summary
This study was designed to see if adding the immunotherapy drug pembrolizumab to standard hormone therapy and radiation could improve outcomes for men with high-risk prostate cancer that hasn't spread. The trial was withdrawn before enrolling any participants, so no results are available. It aimed to measure how well the combination killed cancer cells and what side effects occurred.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.